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Convection enhanced delivery (CED) is a method of direct injection to the brain that can achieve
widespread dispersal of therapeutics, including gene therapies, from a single dose. Non-viral, nano-
complexes are of interest as vectors for gene therapy in the brain, but it is essential that administration
should achieve maximal dispersal to minimise the number of injections required. We hypothesised that
anionic nanocomplexes administered by CED should disperse more widely in rat brains than cationics of
similar size, which bind electrostatically to cell-surface anionic moieties such as proteoglycans, limiting
their spread. Anionic, receptor-targeted nanocomplexes (RTN) containing a neurotensin-targeting pep-
tide were prepared with plasmid DNA and compared with cationic RTNs for dispersal and transfection
efﬁciency. Both RTNs were labelled with gadolinium for localisation in the brain by MRI and in brain
sections by LA-ICP-MS, as well as with rhodamine ﬂuorophore for detection by ﬂuorescence microscopy.
MRI distribution studies conﬁrmed that the anionic RTNs dispersed more widely than cationic RTNs,
particularly in the corpus callosum. Gene expression levels from anionic formulations were similar to
those of cationic RTNs. Thus, anionic RTN formulations can achieve both widespread dispersal and
effective gene expression in brains after administration of a single dose by CED.
 2013 The Authors. Published by Elsevier Ltd. Open access under CC BY license.1. Introduction
Genetic therapies involve the enhancement, replacement,
modiﬁcation, regulation and silencing of gene expression and offer
great promise for the treatment of a wide range of diseases, of the
central nervous system (CNS), including neurodegenerative,
neuromuscular and metabolic diseases as well as cancers, many of
which are currently untreatable [1e5]. Safe, but efﬁcient delivery of
therapeutic nucleic acids, however, remains a major technological
barrier to the development of clinical therapeutics of the CNS.Ltd. Open access under CC BY license.Nanocomplexes for gene delivery are of interest as alternatives to
viral vectors as they can package a wider range of nucleic acids
ranging from siRNA molecules of 20 or so nucleotides to tens of
kilobases of plasmid DNA, and are less immunogenic than viruses
allowing more effective repeated dosing of gene therapies [6,7].
Nanocomplexesmay be delivered to the brain by the systemic route
or by direct injection. Systemic delivery is limited in efﬁcacy by
the almost impermeable nature of the blood brain barrier (BBB)
and rapid clearance of nanocomplexes from the circulation by the
reticuloendothelial system (RES), particularly in the liver [8e10].
Direct injection methods such as intraparenchymal, intra-
cerebroventricular and intrathecal injection, depend on diffusion
for drug dispersal and so are limited in their dispersal by drug
concentration and require injections at multiple sites to achieve
widespread coverage of the brain.
In recent years, convection-enhanced delivery (CED) has been
shown to achieve widespread distribution of therapeutics in the
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vectors [12e14]. CED utilises extremely ﬁne intracranial catheters,
implanted directly into the brain or spinal cord and distributes
therapeutic agents along a pressure gradient generated between the
catheter tip and the extracellular space, achieving controlled, ho-
mogeneous distribution of drugs over distances of up to 5 cm from
the catheter tip in human brains [15]. Clinical trials involving
administration of nanoparticles for gene therapy into the brain by
CED have already been performed in patients with primary brain
tumours [16,17], but more efﬁcient formulations are required that
achievewidespread dispersal and therapeutic delivery froma single
administration.
Previous studies have shown that for widespread dispersal in
the brain by CED, nanoparticles should be anionic or neutral rather
than positively charged [18e20] and less than 200 nm [20]. Anionic
liposomal complexes, however, have not been developed as
extensively as cationic gene delivery complexes due to poor pack-
aging of DNA and poor transfection efﬁciency [21,22]. In recent
studies nucleic acid packaging into anionic complexes has been
improved by various strategies, one of which involved combining
anionic liposomes with polycationic protamine as an electrostatic
bridge between the liposome and the nucleic acid [23,24]. In this
study we have used a similar strategy to formulate an anionic
receptor-targeted nanocomplex (RTN) comprising a mixture of a
peptide containing a cationic oligolysine domain for DNA pack-
aging and a neurotensin, receptor-targeting domain, and an anionic
liposome. A similar cationic RTN formulation described previously
[25] was also prepared containing the same peptide and plasmid,
but a cationic liposome instead of an anionic liposome. In this study
anionic and cationic RTNs, labelled with a gadolinium contrast
agent and a rhodamine ﬂuorophore, were compared for their bio-
physical properties then administered to rat brains by CED and
their distribution analysed by MRI in whole brain and in tissue
sections by LA-ICP-MS and ﬂuorescence microscopy. Transgene
expression was assessed by qRT-PCR and ﬂuorescence microscopy
for green ﬂuorescent protein (GFP) reporter gene expression.2. Materials and methods
2.1. Materials
Lipids (Supplementary Table 1); 1,2-dioleoyl-sn-glycero-3-phospho-(10-rac-
glycerol) (DOPG), 1,2-dioleoyl-3-trimethylammonium-propane (DOTAP), 1,2-
dioleoyl-sn-glycero-3-phosphoethanolamine-N-(lissamine rhodamine B sulfonyl)
(DOPE-Rhodamine) and 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE)
were purchased from Avanti Polar Lipids Inc. (Alabaster, Alabama, USA). GdDOTA(-
GAC12)2 was synthesised as described by Kielar et al. [26]. Neurotensin (Nt) targeting
peptide, its scrambled version (NtS) and the control peptide K16 (Supplementary
Table 2) were synthesized on a MultiSynTech Syro peptide synthesizer using
commercially available Fmoc amino acids (Novabiochem, Nottingham, UK) and
standard automated protocols, as described previously [25]. The plasmid pCI-Luc
consists of the luciferase gene from pGL3 (Invitrogen, Paisley, UK) subcloned into
pCI (Promega, Southampton, UK). The plasmid pEGFP-N1 (4.7 kb) containing the
gene for enhanced green ﬂuorescent protein (GFP) was obtained from Clontech
(Basingstoke, UK). 100 nm polystyrene nanospheres were purchased fromTable 1
LPD nanocomplex composition and associated size and zeta potential. Measurements were t
scattering.
LPD Nanocomplex Charge Ratio (L:P:D)
Liposome Peptide DNA
Cat K16 Anionic Liposome (0.5) K16 (5) pCI-Luc/eGFP (1
Ani K16 Anionic Liposome (3) K16 (2) pCI-Luc/eGFP (1
Cat NtS Anionic Liposome (0.5) NtS (5) pCI-Luc (1)
Ani NtS Anionic Liposome (3) NtS (2) pCI-Luc (1)
Cat Nt Anionic Liposome (0.5) Nt (5) pCI-Luc/eGFP (1
Ani Nt Anionic Liposome (3) Nt (2) pCI-Luc/eGFP (1Phosphorex Inc. (Hopkinton, MA, USA) with both cationic (þ48.1 mV, orange Ex/EM
520/540 nm) and anionic (47.9 mV, blue Ex/Em 360/440 nm) charges. The oligo-
nucleotide primers and standards for qRT-PCR were provided by qStandard (Mid-
dlesex, UK) and were as follows: eGFP: forward primer 50-CTTCAAGATCCGC
CACAACAT-30 and reverse primer 50-GGTGCTCAGGTAGTGGTTGTC-30; Rpl13: for-
ward primer 50-CCCTACAGTTAGATACCACACCAA-30 and reverse primer 50-GATAC-
CAGCCACCCTGAGC-30; Beta actin: forward primer 50- ACGGTCAGGTCATCACTATCG-
30 and reverse primer 50-AGCCACCAATCCACACAGA-30; Sdha: forward primer 50-
TGGACCTTGTCGTCTTTGG-30 and reverse primer 50-TTTGCCTTAATCGGAGGAAC-30 .
2.2. Liposome formulation
Liposomes were formulated with lipid mixtures at speciﬁc molar ratios as fol-
lows; cationic liposomes DOTAP:DOPE:DOPE-Rhodamine:GdDOTA(GAC12)2 and
anionic liposomes DOPG:DOPE:DOPE-Rhodamine:GdDOTA(GAC12)2 both at a molar
ratio of 35:49:1:15 mol% respectively. Liposomes were prepared by dissolving the
individual lipids in chloroform at 10 mg/mL and mixing them together, followed by
rotary evaporation to produce a thin lipid ﬁlm. Lipids were then rehydrated with
sterile water whilst rotating overnight and then sonicated for an hour in a water
bath to reduce the size to unilamellar liposomes.
2.3. Nanocomplex formulation and biophysical characterisation
LPD nanocomplex formulations were prepared by mixing aqueous solutions of
anionic liposome (L), peptide (P) and plasmid DNA (D) at charge ratios of 3:2:1
(14.1:1.15:1 weight ratio) for anionic formulations and 0.5:5:1 (2.35:2.9:1 weight
ratio) for cationic formulations, diluted to 0.01 mg/mL (DNA) in OptiMEM (Invi-
trogen, Paisley, UK) for in vitro transfections, diluted to 0.005 mg/mL (DNA) in sterile
water for biophysical characterisation and diluted to 0.32 mg/mL (DNA) in sterile
water for in vivo experiments. Six nanocomplex formulations were produced
(Table 1), with a targeting peptide neurotensin (Nt), a scrambled neurotensin (NtS)
and a non-targeting K16 peptide. Size and charge of liposomes, nanocomplexes and
nanospheres was analysed using a Malvern Nano ZS (Malvern, UK) at a temperature
of 25 C, viscosity of 0.89 cP and a refractive index of 1.33.
2.4. In vitro transfections
The murine neuroblastoma cell line Neuro-2A (ATCC, Manassas, VA, USA) was
maintained in Dulbecco’s Modiﬁed Eagle Medium, 1% non-essential amino acids,
1 mM sodium pyruvate and 10% FCS (Invitrogen, Paisley, UK) at 37 C in a humidiﬁed
atmosphere in 5% carbon dioxide. Cell transfections were performed as previously
described [25], brieﬂy, cellswere seeded at 2104 perwell in 96-well plates in 175 mL
of complete. 24 h later 25 mL of the nanocomplex formulations (Table 1) in OptiMEM,
containing 0.25 mg of plasmid DNA was added to the cells in replicates of six. Plates
were centrifuged at 1500 rpm for 5min (400 g) and incubated for 24 h at 37 C. Cells
were then lysed and a chemiluminescence assay performed to measure transfected
luciferase activity (Promega, Southampton, UK) and protein concentration deter-
mined using a Bio-Rad protein assay (Hemel Hempstead, UK). Luciferase activitywas
expressed as RLU per milligram of protein. Cell viability assays were performed with
the CellTiter 96 Aqueous One Solution Cell Proliferation Assay (Promega, South-
ampton, UK). Luciferase, protein concentration and toxicity measurements were
performed in an Optima Fluostar microplate reader (BMG Labtech, Aylesbury, UK).
2.5. In vivo Brain delivery
All animal experiments were carried out with licences issued in accordance
with the United Kingdom Animals (Scientiﬁc Procedures) Act 1986 (UK). For all
experiments male Wistar rats (B&K Universal, Hull, UK) were anaesthetised and
placed in a stereotactic frame, burr holes were drilled to allow cannula implanta-
tion to corpus callosum on the left and striatum on the right hand side of the brain
was via a 220 mm outer diameter fused silica cannula at a rate of 0.5 mL/min at each
site (2.5 mL for corpus callosum and 5 mL for striatum) using an infusion pump
(World Precision Instruments, Inc, Sarasota, FL, USA). Following infusion, theaken immediately after formation and 150 days post, as measured by dynamic light
Size (nm) Zeta PD (mV)
Day 0 Day 150 Day 0 Day 150
) 196.5 (4.4) 147.8 (2.6) þ36.1 (0.5) þ37.4 (0.6)
) 170.6 (7.1) 159.5 (3.0) 44.4 (4.2) 61.1 (0.5)
181.1 (4.5) 153.2 (2.9) þ31.5 (0.7) þ31.3 (2.2)
254.0 (3.3) 182.8 (5.2) 61.8 (2.2) 55.5 (0.8)
) 216.9 (6.8) 172.4 (2.1) þ30.0 (1.1) þ31.6 (0.5)
) 177.6 (1.4) 150.1 (5.8) 61.6 (6.5) 65.4 (3.3)
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were killed by transcardial perfusion ﬁxation using 4% paraformaldehyde (pH 7.4)
under terminal anaesthesia. Animals were culled 48 h after administration with
cationic and anionic nanospheres (n ¼ 2 per nanosphere) and cationic and anionic
liposomes (n ¼ 3 per formulation, Supplementary Table 3) for analysis by ﬂuo-
rescence histology. Rats administered with cationic or anionic nanocomplexes
containing targeting peptide Nt or the control peptide K16 (Table 1) (n ¼ 4 per
formulation and time point) were culled at 4 and 48 h after treatment for analysis
by MRI and ﬂuorescence histology.
2.6. MRI
MRI measurements were performed on a 9.4T VNMRS horizontal bore scanner
(Varian Inc. Palo Alto, CA) using a 59/26 Rapid quadrature volume coil. Fixed rat
brains were imaged using a T1-weighted gradient echo 3D sequence (TR ¼ 17 ms,
TE ¼ 4 ms, FA ¼ 52 , 40 mm isotropic resolution, Ave ¼ 6). Distribution volumesFig. 1. In vitro transfection and viability assays of cationic and anionic nanocomplexes in Ne
cationic and anionic formulations containing the targeted peptide Nt compared to two non-t
assay (A). Cell viability after incubation with targeted compared to non-targeted as bo
replicates  standard deviation with t-tests performed to calculate signiﬁcant differences.were measured by manually segmenting the hyperintensities caused by the gad-
olinium containing nanocomplexes using Amira (Visage Imaging Inc, San Diego, CA,
USA).
2.7. Histological assessment
Brains were sectioned as 35 mm slices using a Leica CM1850 cryostat (Leica
Microsystems, Wetzlar, Germany), washed with phosphate buffered saline and
mounted in Vectashield (Vectorlabs, Burlingame, CA) on gelatin-coated slides and
coverslipped, prior to ﬂuorescent imaging with a Leica DM5500 microscope (Leica
Microsystems, Wetzlar, Germany) and digital camera (MBF, Germany).
2.8. LA-ICP-MS
The laser ablation system (UP-266 Macro LA system, Nd:YAG l 266 nm, New
Wave Research, Cambridgeshire, UK) was conﬁgured to perform multiple paralleluro-2A cells. Transfection efﬁciency and targeting speciﬁcity of the nanocomplexes as
argeted formulations containing peptides, K16 and NtS measured by a luciferase activity
th cationic and anionic nanocomplex formulations (B). Values are the means of 6
**p < 0.01, ***p < 0.001.
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of 155 mmwas utilised for interrogation of sections. Laser energy was in the range of
1.4 mJ at a frequency of 10 Hz, and the scanning speed was set to 60 mm/s. The
interrogated area was in the region of 140 mm2. The line rasters were separated by
310 mm, to prevent contamination of adjacent tissue with previous line raster runs.
Complete analysis runtimewas 178 min per section. Elemental maps were produced
using the Graphis software package (Kylebank Software Ltd., Ayr, UK). The isotopes
157Gd and 57Fe were monitored in a time-resolved mode using an Agilent 4500 ICP-
MS and were selected on the basis of high-percentage abundance and minimal
interferences.2.9. qRT-PCR
Rat brains (n ¼ 3 per formulation) were collected in RNAlater (Invitrogen,
Paisley, UK) and total RNA was extracted using the RNeasy kit according to the
manufacturer’s instructions (Qiagen, Crawley, UK). RNA was checked for integrity
using the Agilent 2100 Bioanalyzer (Wokingham, UK) and all samples had a RNA
integrity number (RIN) of more than 8 indicating high quality RNA. Prior to reverse
transcription, each RNA sample underwent DNase treatment (Invitrogen) to
eliminate any potential genomic DNA contaminants. First-strand DNA was syn-
thesized from 1 mg of DNase-treated RNA, using random hexamers and Superscript
II reverse transcriptase (Invitrogen, Paisley, UK) in a 1 h reaction at 37 C eGFP, rat
Succinate dehydrogenase complex subunit A (Sdha), rat Ribosomal protein L13
(Rpl13) and rat beta actin mRNA levels were then quantiﬁed by SYBR Green
quantitative real-time polymerase chain reaction (qPCR) using an ABI PRISM 7000
Sequence Detection System (Applied Biosystems, Warrington, UK). The qPCR assay
conditions were: stage 1, 50 C for 2 min; stage 2, 95 C for 10 min; stage 3, 95 C
for 15 s, then 60 C for 1 min; repeated 40 times. Ampliﬁcation efﬁciency was 102%
(eGFP), 102% (beta actin), 103% (Rpl13), and 105% (Sdha). Copy numbers for eGFP
and the three housekeeping genes were derived from standard curves constructed
of puriﬁed PCR products generated for each speciﬁc primer pair ranging from 107
to 101 copies for eGFP, Rpl13, Sdha and beta actin. Copy numbers of iNOS were
normalized against the geometric mean of Rpl13 and beta actin, which were the
most stable genes.2.10. Statistical analysis
Data presented in this study are expressed as the mean  standard
deviation and were analysed using a two-tailed, unpaired Student t-test where
applicable.Fig. 2. In vivo distribution of cationic and anionic nanospheres in the striatum and corpus ca
or anionic (B,D) ﬂuorescently-labelled, 100 nm nanospheres into either the striatum (A,B) or
to visualise the distribution of the nanospheres charge 48 h after administration from th
distribute further than their cationic counterparts. Scale bars ¼ 500 mm.3. Results
3.1. Biophysical characterisation of nanocomplexes
A series of targeted and non-targeted cationic and anionic
nanocomplex formulations were generated and characterised for
size and charge. Targeted anionic and cationic formulations
both contained a peptide with a cationic oligolysine domain for
efﬁcient packaging of plasmid DNA and a neurotensin (Nt) receptor
binding domain for cell targeting. The peptide was combined with
an anionic liposome (DOPG:DOPE:DOPE-Rhodamine:GdDOTA(-
GAC12)2) and plasmid DNA which, at appropriate ratios and in the
right order of mixing, created nanocomplexes with either a net
cationic or anionic surface charge. The anionic liposome compo-
nent of the nanocomplexes also contained lipids labelled with
gadolinium and rhodamine to enable detection of nanocomplexes
by both magnetic resonance imaging (MRI) and ex vivo histology
[19,27e29] (Supplementary Table 1). In non-targeted formulations
the Nt-targeting motif was scrambled (NtS) peptide or removed,
leaving just K16. The resulting nanocomplexes varied in size from
170 nm to 250 nm, while zeta potential measurements conﬁrmed
the predicted anionic and cationic surface charges of each formu-
lation (Table 1). All of the liposomes and nanocomplexes formed
had a polydispersity index of less than 0.3, indicating a mono-
disperse population of particles [30,31]. The properties of the
nanocomplexes, based on their size and charge, were in the region
stated by MacKay et al. required for increased delivery distribution
when administered to the brain by CED [18].
3.2. In vitro cell transfections
In vitro cell transfections were performed on Neuro-2A neuro-
blastoma cells, to compare transfection efﬁciencies of anionic
nanocomplexes with their cationic homologues. These cells werellosum after convection-enhanced delivery. Rats were administered with cationic (A,C)
corpus callosum (C,D). Tissue sections were analysed by ﬂuorescence microscopy (A-D)
e injection site (white arrowheads). The anionic charged nanospheres were found to
Fig. 3. MRI of gadolinium labelled cationic and anionic liposomes to measure in vivo distribution in the striatum and corpus callosum after convection-enhanced delivery. Opti-
mised 3D T1-weighted gradient echo scans were performed to allow visualisation of the gadolinium in the nanocomplexes, seen as hyperintensities, in both cationic (A) and anionic
(B) liposomes. These data were reconstructed as 3D datasets to allow volumetric analyses between the cationic (C) and anionic (D) liposomes distribution after convection-
enhanced delivery into the striatum (green) and corpus callosum (purple). Fluorescence microscopy was used to visualise cationic (E,F) and anionic (G,H) liposome distribution,
by utilising the incorporated rhodamine label, in the striatum (E,G) and corpus callosum (F,H). The MRI data was used to calculate distribution of the cationic and anionic liposomes
in the striatum and corpus callosum 48 h post administration (I). These results demonstrate that the anionic charged liposomes distribute further than the cationic equivalent
liposomes. Values are the means of 3 replicates  standard deviation with t tests performed to calculate signiﬁcant differences. **p < 0.01, scale bars ¼ 500 mm.
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Fig. 4. In vivo distribution volume assessment of cationic and anionic nanocomplexes into the striatum and corpus callosum after convection-enhanced delivery. Reconstructed 3D
datasets of optimised 3D T1-weighted gradient echo scans allowed volumetric analyses between the cationic (A) and anionic (B) nanocomplexes distribution after convection-
enhanced delivery. Distribution of the anionic and cationic nanocomplexes in the striatum (green) and corpus callosum (purple) at both 4 and 48 h post administration (C) and
as Nt or K16 formulations was measured (D). Values are the means of 8 animals  standard deviation with t-tests performed to calculate signiﬁcant differences. **p < 0.01,
***p < 0.001. (For interpretation of the references to colour in this ﬁgure legend, the reader is referred to the web version of this article.)
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G.D. Kenny et al. / Biomaterials 34 (2013) 9190e92009196reported previously by us to be targeted by cationic nanocomplexes
containing the Nt-targeted peptide [25]. Interestingly, the Nt
receptor-targeted anionic formulations displayed similar levels of
transfection efﬁciency to the cationic, Nt-targeted formulations.
Both anionic and cationic Nt-targeting formulations displayed
signiﬁcant levels (p < 0.01) of transfection enhancement over both
of their non-targeted nanocomplexes homologues containingFig. 5. Corroboration of MRI distribution of cationic and anionic Nt-nanocomplexes into th
weighted gradient echo scans were performed to allow visualisation of the gadolinium
nanocomplex and cationic (B) and anionic (D) Nt-nanocomplexes. Corresponding LA-ICP-MS
cationic Nt-nanocomplexes (F,J), anionic K16-nanocomplexes (G,K) and anionic Nt-nanocom
Florescence microscopy was also utilised to conﬁrm distribution of the cationic K16-nanocom
anionic Nt-nanocomplexes (P,T) by utilising the incorporated rhodamine lipid. White arroweither the NtS or K16 peptides (Fig. 1A), while cytotoxicity levels
were minimal (Fig. 1B).
3.3. In vivo Brain delivery of nanospheres and liposomes
The hypothesis that anionic nanocomplexes would disperse
further than cationic nanocomplexes in the brain by CEDwas testede striatum and corpus callosum after convection-enhanced delivery. Optimised 3D T1-
in the nanocomplexes, seen as hyperintensities, in cationic (A) and anionic (C) K16-
elemental maps of gadolinium (E-H) and iron (I-L) for cationic K16-nanocomplexes (E,I),
plexes (H,L) demonstrated MR signal intensities were due to gadolinium and not iron.
plexes (M,Q), cationic Nt-nanocomplexes (N,R), anionic K16-nanocomplexes (O,S) and
heads ¼ the injection sites. Scale bars ¼ 500 mm.
Table 2
In vivo LPD nanocomplex LA-ICP-MS and MRI assessment. LA-ICP-MS was used to
measure the peak intensity of iron (Fe) and gadolinium (Gd) in the brain samples on
both left and right sides and then compared to the MRI peak signal intensity.
LPD
Nanocomplex
Timepoint
(h)
Fe counts Gd counts MRI peak intensity
L R L R L R
Cat K16 4 14700 11700 152000 15100 1.9023 1.0585
15800 24500 84000 112000 1.9776 2.0587
48 12800 2780 359000 42900 1.9636 1.0051
3060 5650 1930 191000 1.0237 1.7054
Ani K16 4 4230 4820 88700 153000 2.3509 2.2860
10100 21600 182000 273000 2.0083 2.08
48 13100 6910 575000 23200 1.8359 1.1648
3640 14000 120000 404000 1.7121 1.8367
Cat Nt 4 13500 4700 247000 16300 1.3918 0.9266
19200 5580 270000 6340 1.2937 1.1338
48 1860 1100 1420 12400 0.9526 1.4698
6750 36100 276000 5590 1.9917 1.0746
Ani Nt 4 19400 6360 415000 59200 2.8518 1.7748
6410 4090 202000 104000 2.5513 1.9248
48 7820 7030 65000 1720 2.1743 1.0820
23500 4530 326000 7640 2.0763 1.0517
G.D. Kenny et al. / Biomaterials 34 (2013) 9190e9200 9197with synthetic polystyrene nanospheres of 100 nm in size and
cationic or anionic charges, both labelled with ﬂuorophores (n ¼ 2
per nanosphere). Nanospheres were administered by CED to rat
brains in the striatum and corpus callosum then tissue sections
were analysed by ﬂuorescence microscopy at 4 h after adminis-
tration (Fig. 2). In both regions of the brain the cationic nano-
spheres remained close to the cannula insertion site, while the
anionic nanospheres showed a radius of dispersal of up to 2 mm
from the site of the cannula tip, supporting the hypothesis that
anionic particles would disperse better in the brain after CED.
However, accurate analysis of dispersal of the nanospheres by
ﬂuorescence microscopy is difﬁcult due to the nature of histology.
The hypothesis was then further tested by CED administration
to rat brain of cationic and anionic liposomes of similar size,
163.1 nm and 140.8 nm respectively (Supplementary Table 3). The
liposomes were labelled with gadolinium and rhodamine to allow
the evaluation and quantiﬁcation of distribution by MRI and ﬂuo-
rescence microscopy. It was apparent from both the MRI and
ﬂuorescence analysis that, as with the nanospheres, the cationic
liposomes were restricted to the vicinity of the injection site while
the anionic liposomes weremore widely dispersed, with a radius of
dispersal of up to 1 mm.
The raw data from the MRI analysis (Fig. 3A, B) was used to
reconstruct a 3D image of the rat brain showing the extent of
liposome distribution (Fig. 3C, D) and the distribution volumes for
each liposome were then calculated in each area of the brain. The
distribution volumes of anionic liposomes were fourefold higher in
the corpus callosum than the cationic liposomes, while there was
no signiﬁcant difference between them in the striatum (Fig. 3I).
These results were corroborated with ﬂuorescence microscopy
utilising the rhodamine incorporated into the liposome bilayer,
which also displayed increased distribution in the anionic lipo-
somes (Fig. 3EeH). The MRI also illustrated inaccuracy in the in-
jection site and reﬂux of the nanocomplexes along the injection
track (Fig. 3C, D). This increased distribution in the brain of anionic
nanospheres and anionic liposomes was supportive evidence for
further studies into the potential for widespread distribution of
anionic nanocomplexes in the brain after CED.
3.4. In vivo Brain delivery of nanocomplexes
Neurotensin receptor-targeted and non-targeted, anionic and
cationic nanocomplexes were prepared (Table 1) carrying the GFP
reporter gene and administered to rat brains by CED in the striatum
and corpus callosum. MRI analysis and 3D reconstructions indi-
cated that the anionic nanocomplexes were more widely distrib-
uted than the cationics in both regions. Distribution volumes,
calculated from the 3D reconstructions (Fig. 4A, B), were approxi-
mately seven-fold higher for anionic nanocomplexes in both the
corpus callosum and striatum than cationic formulations (Fig. 4C,
D). There were no signiﬁcant differences in brain volume distri-
bution at 48 h compared to 4 h by MRI (Fig. 4C), indicating that
passive diffusion post-delivery was not occurring and no differ-
ences in distribution due to the peptide (Fig. 4D).
Analysis of the pattern of rhodamine distribution by ﬂuores-
cence microscopy (Fig. 5MeT) and gadolinium by LA-ICP-MS
(Fig. 5EeH) in brain sections indicated a similar distribution
pattern of the MRI signal (Fig. 5AeD) for each sample. However,
histological analysis of each brain sample revealed evidence of
tissue damage and haemorrhage in almost all animals treated by
CED due to the insertion of the cannula. We have shown previ-
ously that accumulation of iron from haemoglobin at sites of
haemorrhage can lead to some ambiguity in MRI analysis [19,32].
To address this secondary analysis of tissue sections was per-
formed by laser ablation inductively coupled mass spectrometry(LA-ICP-MS) to detect gadolinium distribution from the nano-
complex formulation and iron accumulation from haemorrhage.
LA-ICP-MS analysis of 57Fe in sections from brains treated with
cationic and anionic nanocomplexes indicated a small degree of
haemorrhage near the burr hole in the cranium and, additionally
for the anionic sample, near to the site of injection in the corpus
callosum (Fig. 5IeL). Two sections from the brain of each animal in
each group were analysed for peak intensity of counts for 157Gd
and 57Fe and correlated with peak signal intensity from MRI,
which visually correlated with the 157Gd signal distribution anal-
ysis (Table 2). Signals for 57Fe were detected in each case with
counts in the range of 3e9% of the 157Gd counts. In samples where
57Fe was relatively high compared to 157Gd, anything above 35%,
this was attributable to low counts for 157Gd, of less than 15,000,
due most likely to a poor injection, e.g., sample reﬂux, which was
supported by the lack of MRI signal detected in the same samples.
There was no signiﬁcant reduction of Gd counts or MRI signal
intensity from 4 h to 48 h.
3.5. Gene expression from nanocomplexes in the brain
Brain tissue sections analysed by ﬂuorescence microscopy
showed evidence of GFP expression (Fig. 6AeH), which appeared to
correlate well with the MRI distribution analysis (Fig. 4A, B). GFP
ﬂuorescence was located in the vicinity of the cannula insertion site
in the striatum for both cationic and anionic formulations. How-
ever, more widespread GFP expression was detected in the corpus
callosum, particularly for the anionic formulations (Fig. 6B, D, F, H).
As autoﬂuorescence can be problematic with GFP ﬂuorescence
analysis, gene expression was also analysed by quantitative PCR
ampliﬁcation of mRNA (Fig. 6I) from the two regions of the brain.
Highest expression levels were achieved by the cationic formula-
tions in the corpus callosum, however the anionic formulations
appeared to give comparable levels of expression to the other
cationic formulations. The Nt targeting peptides gave higher levels
of transfection than those containing the non-targeted K16 peptide
in all cases, suggesting targeting with both anionic and cationic
formulations.
4. Discussion
Systemic delivery of gene therapies to the brain is highly inef-
ﬁcient due to the impermeability of the blood brain barrier and so
Fig. 6. Effective reporter gene delivery to the striatum and corpus callosum by cationic and anionic, with Nt targeting and K16 non-targeting LPDs assessed by ex vivo ﬂuorescence
microscopy and qRT-PCR. Fluorescence microscopy of the eGFP reporter gene was used to visualise cationic (A,B) and anionic (C,D) Nt-nanocomplex gene delivery in the striatum
(A,C) and corpus callosum (B,D). eGFP expression mediated by cationic (E,F) and anionic (G,H) K16-nanocomplex in the striatum (E,G) and corpus callosum (F,H) was also visualised.
Functional delivery of the eGFP plasmid by the cationic and anionic nanocomplexes with Nt and K16 peptides was also assessed ex vivowith qRT-PCR (I). Values represent the mean
of 3 animals per group  standard deviation with t-tests performed to determine signiﬁcant differences. *p < 0.05, scale bars ¼ 500 mm.
G.D. Kenny et al. / Biomaterials 34 (2013) 9190e92009198direct injection methods are under development. CED is the most
effective method of direct injection, but anionic or neutral nano-
particles are required to achieve widespread dispersal [18]. Syn-
thetic gene delivery formulations, however, are most often self-
assembling formulations of cationic liposomes or cationic poly-
mers that form strongly cationic nanocomplexes. While effective
for DNA packaging and cell binding leading to strong transfection ofsome applications, their cationic charge is problematic in vivo in
that it leads to non-speciﬁc interactions with negatively charged
cellular and extracellular matrix components, serum proteins
and enzymes. This can lead to aggregation and rapid clearance from
the circulation by the reticuloendothelial system following sys-
temic administration [33], hepatotoxicity [34] and a strong in-
ﬂammatory response [35]. PEGylation sterically stabilizes cationic
G.D. Kenny et al. / Biomaterials 34 (2013) 9190e9200 9199nanoparticles, which minimizes their non-speciﬁc interaction
in vivo, and thusmay prolong the circulation time leading to nucleic
acid accumulation in tissues other than liver, including tumours
[36,37], but PEGylationmay also impede cell uptake and endosomal
escape yielding lower levels of gene expression [38]. We therefore
decided to develop anionic, non-PEGylated nanocomplex formu-
lations for brain delivery.
Nucleic acid packaging into anionic self-assembling complexes
has been achieved by three general strategies; 1) combining
anionic liposomes with polycationic protamine as an electrostatic
bridge between the liposome and the nucleic acid [23,24], 2)
combining anionic liposomes with calcium cations as the bridge
[39e41], or, 3) forming an electrostatic coating of polyglutamate
around a core cationic nanoparticle [42e44]. In vivo studies with all
strategies have been reported [23,39,44,45] with evidence of efﬁ-
cacy and improved toxicity and safety compared to cationic for-
mulations. Anionic liposomes injected systemically displayedmuch
lower levels of liver accumulation than cationic liposomes [46]
while anionic nanoparticles have been used to prolong circulation
time and to increase delivery to tumours by passive targeting uti-
lising the enhanced permeability and retention effect [43,45e47] in
one case with a targeting moiety [23].
In seeking to develop new more efﬁcient nanocomplexes for
widespread dispersal of transfection in the brain by CED, we ﬁrst
examined the effect of charge on distribution of nanoparticles
utilising both ﬂuorescent nanospheres and ﬂuorescent,
gadolinium-labelled liposomes with cationic and anionic charges.
Techniques of analysis included ﬂuorescence microscopy analysis
of both nanospheres and liposomes, and MRI in whole brains for
the liposomes. In both settings the distribution of the anionic
species was more widespread than the equivalent cationic species
of similar size. Nanocomplex formulations of lipids and peptides
labelled with ﬂuorophore and gadolinium, also distributed further
when their surface charge was anionic rather than cationic. Further
analysis by LA-ICP-MS provided supportive evidence that the MRI
in each case was unambiguously attributable to the distribution of
gadolinium associated with the nanocomplex. This is important for
in vivowork, and possibly for clinical studies, as MRI analysis of the
gadolinium distribution alone is sufﬁcient to determine the nano-
complex distribution, which can be measured in real time and at
multiple time points. MRI allows accurate quantiﬁcation of distri-
bution, which is not possible by other techniques such as ﬂuores-
cence microscopy analysis of tissue sections. In addition MRI
illustrated the difﬁculty in accurately hitting the injection site of
interest, as on occasion nanocomplex reﬂux up the needle track
could be seen.
Anionic nanocomplex distribution volume in the striatum was
signiﬁcantly less than the same formulation in the corpus callosum,
which is due, most likely, to the more compact nature of the
striatum requiring pericellular transport, whilst in the corpus cal-
losum the nanocomplexes were better able to travel between the
nerve ﬁbres. Thus, in the striatum, the size of the anionic liposomes,
around 140 nm, may be a signiﬁcant factor in limiting their dis-
tribution by CED. The distribution of the nanoparticles examined
here is governed by convection rather than diffusion, as there was
no increase in distribution detected 48 h after injection, which also
indicates the potential for monitoring of delivery for several days
after treatment. In future studies, it might be advantageous to
formulate smaller nanocomplexes and to modify the coating to
include a PEG layer to increase the distribution by diffusion as
recently described by Nance et al. [20].
The qRT-PCR analysis demonstrated that the cationic nano-
complexes with the neurotensin targeting peptide had the greatest
expression in the corpus callosum. In both cationic and anionic
nanocomplexes the neurotensin peptide appeared to demonstratehigher transfection efﬁciencies when compared to the non-
targeted control. However, due to variability and sample size only
the neurotensin-targeted cationic nanocomplexes in the corpus
callosum were statistically signiﬁcant. Despite the anionic nano-
complexes not achieving the same expression in vivo as the
cationic, the results offer promise that with minor modiﬁcations
transfection efﬁciency can be signiﬁcantly increased. This indicates
that these anionic nanocomplexes, with their improved distribu-
tion, can be used to deliver therapeutic DNA to a larger volume than
their cationic counterparts and still deliver the therapeutic payload
to the appropriate cells.
The versatility of the nanocomplex platform described here al-
lows for further optimisation by changing of the targeting moieties
leading to speciﬁc cellular uptake of a deﬁned cell type. Also, the
liposome bilayer could be altered to include other imaging tracers
or to further enhance the transfection efﬁciency or distribution
properties. The promising results presented here suggest that these
nanocomplexes could potentially used in the delivery of thera-
peutic genes towhite matter diseases such asmultiple sclerosis and
Alzheimer’s disease in humans as the delivery is greatest in the
corpus callosum, affording large coverage. Therefore these results,
taken alongside other clinical trials of CED [48e50], demonstrated
that combining CED with anionic nanocomplexes has great po-
tential for the treatment of a wide range of clinical neurodegener-
ative diseases.
5. Conclusions
In this study we have developed anionic nanocomplex formu-
lations of liposomes, cationic-targeting peptides and plasmid DNA
which we have shown to have increased distribution in the brain,
particularly in the corpus callosum, by MRI, ﬂuorescence histology
and LA-ICP-MS. Neurotensin receptor-mediated transfection was
demonstrated by GFP expression and qRT-PCR analysis, clearly
showing that our nanocomplexes have real potential for the
treatment of a wide range of neurodegenerative diseases.
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